TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02132845

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cytology specimen collection procedure
Description: Undergo collection of tissue and blood samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cytology specimen collection procedure
Description: Undergo collection of tissue and blood samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: targeted therapy
Description: Receive target-directed therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic procedure
Description: Receive standard of care therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03083314

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SELECTIVE AXILLARY LYMPH NODE DISSECTION (SAD)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: COMPLETE AXILLARY DISSECTION (ALND)
Study: NCT03006484

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be needed.
Study: NCT03945838

Intervention type: OTHER
Intervention: Complete Decongestion Therapy
Description: It is given in two phases. First phase includes intensive therapy which aims to reduce the volume of the extremity. Second phase aims to preserve these reductions of volume.~All patients were prescribed lymphedema specific exercises and were advised to walk (for 30 minutes everyday) daywhile taking complete decongestive therapy. They were specifically informed that exercise does not aggravate the severity of their lymphedema.~Short stretch bandages were applied to the patients with self manual lymphatic drainage. Intensive phase was given 5 days a week, and short stretch bandages applied for 23 hours a day with 1 hour interval. To increase the local pressure on the areas required, foams were added. Patients were screened with arm circumferential measurements once a week. After gaining a plateau in the volumes, patients were prescribed compression garments.
Study: NCT05024669

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gluma desensitiser
Description: Gluma desensitiser was used before restoration.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sheildforce Plus desensitiser
Description: Sheildforce Plus desensitiser was used before restoration.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Telio CS desensitiser
Description: Telio CS desensitiser was used before restoration.
Study: NCT04088500

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specific dose on specific days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specific dose on specific days
Study: NCT01257048

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Formoterol Turbuhaler
Description: 9 microgram on visit 5 single dose
Study: NCT01466803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorikonazole
Description: The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
Study: NCT04190290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy Adapted Program
Description: 3 days / week mobilisations and respiratory exercises and body image exercises

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation and Control
Description: Manual muscle test MRC score, peak-expiratory-flow test, hand strength test, 6 minutes walking test, SF-36, EDI-3 and EDQOL
Study: NCT00428558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy (DAUNORUBICINE-CYTARABINE)
Description: A Phase 3 Trial of Systematic versus Response-adapted Timed-SEQUENTIAL Induction in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (DAUNORUBICINE-CYTARABINE)
Description: Chemotherapy induction sequential
Study: NCT00284063

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low back adjustment and MRI
Description: Subjects received a 15 minutes MRI in neutral position, a chiropractic low back spinal manipulation, and a second 15 minute MRI in neutral position.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low back adjustment and MRI
Description: Subjects received a 15 minutes MRI in neutral position, a chiropractic spinal manipulation to the low back, and a second 15 minute MRI in a side posture position.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Subjects received a 15 minute MRI in neutral position and a second 15 minute MRI in neutral position.
Study: NCT04075825

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Darvadstrocel
Description: Allogenic expanded adipose-derived stem cells (eASCs) 5 million cells/ml - suspension for injection darvadstrocel received in previous ADMIRE-CD II study. No drug administration in this study.
Study: NCT02089308

Intervention type: DRUG
Group type: OTHER
Intervention: Test treatment : V0116 transdermal patch

Intervention type: DRUG
Group type: OTHER
Intervention: Test treatment : V0116 transdermal patch

Intervention type: DRUG
Group type: OTHER
Intervention: Reference treatment : Nicotine transdermal patch
Study: NCT01257048

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide/Formoterol Turbuhaler
Description: 320/9 microgram twice daily during 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Turbuhaler
Description: 9 microgram twice daily during 8 weeks
Study: NCT00806741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NG-monomethyl-L-arginine (L-NMMA)
Description: bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: 1μg/kg/min, infusion period 20 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline solution (as placebo)
Description: infusion period 20 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Doppler Flowmetry
Description: blood flow measurements at the temporal neuroretinal rim of the optic nerve head
Study: NCT04190290

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Evaluation and Control
Description: Manual muscle test MRC score, peak-expiratory-flow test, hand strength test, 6 minutes walking test, SF-36, EDI-3 and EDQOL
Study: NCT01115218

Intervention type: PROCEDURE
Intervention: Trabeculectomy
Description: Trabeculectomy with mitomycin C
Study: NCT04065893

Intervention type: PROCEDURE
Intervention: Catheter ablation of ventricular arrhythmia
Description: PVC or VT ablation

Intervention type: DRUG
Intervention: Intensified medical therapy
Description: Dosage increase / new onset of Betablocker / medical antiarrhythmic medication according to guideline and clinical practice
Study: NCT02367495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCB
Description: PCB with Citrate-based excipient
Study: NCT00585351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: 50 mg single dose injection of Ranitidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranitidine
Description: 50 mg single dose injection of Ranitidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 50 mg single dose injection of normal saline (placebo)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg single dose injection of normal saline (placebo)
Study: NCT02089308

Intervention type: DRUG
Group type: OTHER
Intervention: Reference treatment : Nicotine transdermal patch
Study: NCT00585351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advanced notification
Description: Advanced notification of study via faxed consent to local Emergency Room (ER)
Study: NCT01421823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha agonist ointment
Description: 2 weeks local treatment with alpha agonist ointment
Study: NCT04390984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate, Gefitinib
Description: Subjects will be administrated with 500mg apatinib on day 1 and day 12-15, and administrated with gefitinib on day 4-15.
Study: NCT02660801

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Description: A high-velocity and low-amplitude thrust delivered posteroanteriorly to a thoracic vertebra

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal mobilization
Description: Three repetitions of a low-velocity and low-amplitude nonthrust movement delivered posteroanteriorly to a thoracic vertebra
Study: NCT05228327

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusal splint treatment
Description: Occlusal splint was made for 16 patients and they used just this occlusal splint for 3 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Masticatory muscle injection
Description: Lidocaine was injected on 16 patients' three trigger point in the masseter muscle. Injection was repeated 3 times, once a week.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combination of occlusal splint and masticatory muscle injection treatments
Description: Lidocaine was injected on 16 patients' three trigger point in the masseter muscle. Occlusal splint was also made and they started to use the day which first injection was made. And continue to use the occlusal splint for 3 months. Injection was repeated 3 times, once a week.
Study: NCT00408148

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Undistinguishable placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: White film-coated, for oral administration containing 20 mg of active rimonabant
Study: NCT03776825

Intervention type: DEVICE
Intervention: Permacol Paste
Description: Permacol Paste Injection
Study: NCT00742092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: miglustat
Description: Oral miglustat capsules 200 mg t.i.d. (three times a day) for 7 days and a single 200 mg dose on Day 8

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral placebo capsules matching in appearance miglustat capsules given t.i.d. (three times a day) for 7 days and a single dose on Day 8
Study: NCT01870193

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glycine, cysteine (as n-acetylcysteine), alanine
Description: Young controls will receive cysteine plus glycine for 2 weeks~The elderly subjects will be randomized in a double-blinded design to receive either cysteine plus glycine OR alanine for a period of 4 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glycine, cysteine (as n-acetylcysteine), alanine
Description: Young controls will receive cysteine plus glycine for 2 weeks~The elderly subjects will be randomized in a double-blinded design to receive either cysteine plus glycine OR alanine for a period of 4 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glycine, cysteine (as n-acetylcysteine), alanine
Description: Young controls will receive cysteine plus glycine for 2 weeks~The elderly subjects will be randomized in a double-blinded design to receive either cysteine plus glycine OR alanine for a period of 4 months
Study: NCT02756754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: The radiofrequency system will be used as the RFA generator device standard cycle of ablation will be applied in the patient. During RFA, blood pressure, pulse and oxygen saturation will be continuously monitored.
Study: NCT04701463

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-glutamine, L-arginine and calcium beta-hydroxy-beta-methylbutyrate
Description: 2 daily sachets (mid morning and mid afternoon) of an oral dietary supplement with L-glutamine and L-arginine and calcium beta-hydroxy-beta-methylbutyrate

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isocaloric formula
Study: NCT02924896

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Palm olein
Description: 60g of palm olein will be given in a milkshake at breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Palm olein
Description: 60g of palm olein will be given in a milkshake at breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Palm olein
Description: 60g of palm olein will be given in a milkshake at breakfast
Study: NCT00585351

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Advanced notification
Description: Advanced notification of study via faxed consent to local Emergency Room (ER)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No advanced notification
Description: No advanced notification of study via faxed consent to local Emergency Room (ER)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No advanced notification
Description: No advanced notification of study via faxed consent to local Emergency Room (ER)
Study: NCT03169777

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: avelumab
Description: Fully human anti-programmed death-ligand 1 (PD-L1) immunoglobulin (Ig)G1 lambda monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Recombinant human anti-vascular endothelial growth factor (VEGF) IgG1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Recombinant human/mouse chimeric anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: 7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab paclitaxel
Description: 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Human anti-programmed cell death protein 1 (PD-1) IgG4 kappa monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: Omega-3-acid ethyl esters

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: (SBRT)
Study: NCT01421823

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 weeks local treatment with placebo ointment
Study: NCT00806741

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Doppler Flowmetry
Description: blood flow measurements at the temporal neuroretinal rim of the optic nerve head

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Laser Doppler Flowmetry
Description: blood flow measurements at the temporal neuroretinal rim of the optic nerve head

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goldmann applanation tonometer
Description: intraocular pressure measurements

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goldmann applanation tonometer
Description: intraocular pressure measurements

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Goldmann applanation tonometer
Description: intraocular pressure measurements

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: squatting
Description: Subjects will perform squatting for 6 minutes while blood flow is measured

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: squatting
Description: Subjects will perform squatting for 6 minutes while blood flow is measured
Study: NCT04144543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Noise
Description: The white noise was initiated 50 cm away from the baby, with the decibel meter set to an average of 55 decibels. The baby was exposed to white noise for 2 minutes before the procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facilitated Tucking
Description: The baby's arms and legs were held in flexed positions close to the midline of the torso in sidelying position, so the baby was able to move his/her extremities. The baby was held in facilitated tucking position for one minute before the procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Noise+Facilitated Tucking
Description: The baby was exposed to white noise for 1 minute before the procedure. The white noise was initiated 50 cm away from the baby, with the decibel meter set to an average of 55 decibels. At the second minute, when the white noise still continued to play, facilitated tucking was performed at the same time and the baby continued to listen to the white noise for 1 minute while in facilitated tucking position.
Study: NCT03169777

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: recombinant human super agonist interleukin-15 (IL-15) complex

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-021
Description: Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury vaccine
Study: NCT00882778

Intervention type: DRUG
Intervention: eptacog alfa (activated)
Description: Retrospective data collection of the use of activated recombinant human factor VII as prophylaxis in haemophilia patients with inhibitors
Study: NCT01691495

Intervention type: DRUG
Intervention: Fondaparinux
Description: Physician adherence study to Fondaparinux prescribing information for patients with Superficial Vein Thrombosis (SVT) of the lower limbs
Study: NCT04523272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study: NCT00806741

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: squatting
Description: Subjects will perform squatting for 6 minutes while blood flow is measured
Study: NCT03601949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SInergy Cooled Radiofrequency
Description: ablation of low back pain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Management
Description: physical therapy, medications, lifestyle changes
Study: NCT04523272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: A multi-target receptor tyrosine kinase inhibitor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: A multi-target receptor tyrosine kinase inhibitor.
Study: NCT01232686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online disease surveillance data access
Description: In the intervention areas we will give the study participants online access to the Snow disease surveillance system. The system will provide data about the incidents of respiratory and gastrointestinal communicable diseases in the patient population.
Study: NCT03268759

Intervention type: OTHER
Intervention: fMRI
Description: Observation of neural markers of reward processing
Study: NCT03169777

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: RAS yeast vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6207
Description: CEA yeast vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Brachyury yeast vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK
Description: NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion
Study: NCT04509609

Intervention type: OTHER
Intervention: Exon 3 truncating mutation
Description: Any patient affected by LGMD 2E with a genetic diagnosis carrying the truncating mutation c.377_384duplCAGTAGGA on exon 3, both in homozygosis and in heterozygosis
Study: NCT02924896

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Palm olein
Description: 60g of palm olein will be given in a milkshake at breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Palm olein
Description: 60g of palm olein will be given in a milkshake at breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Palm olein
Description: 60g of palm olein will be given in a milkshake at breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Interesterified palm olein
Description: 60g of interesterified palm olein will be given in a milkshake at breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Interesterified palm olein
Description: 60g of interesterified palm olein will be given in a milkshake at breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Interesterified palm olein
Description: 60g of interesterified palm olein will be given in a milkshake at breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Interesterified palm olein
Description: 60g of interesterified palm olein will be given in a milkshake at breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Interesterified palm olein
Description: 60g of interesterified palm olein will be given in a milkshake at breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Interesterified palm olein
Description: 60g of interesterified palm olein will be given in a milkshake at breakfast
Study: NCT02754687

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with capsules that look like the 11β-MNTDC capsules but with no active ingredients